Aramis Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aramisbio.com
A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: A197 Ophthalmic SolutionDrug: Active ComparatorDrug: A197 Vehicle Control
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Aramis Biosciences, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT05238597
- Locations
- 🇺🇸
Aramis Site 113, Birmingham, Alabama, United States
🇺🇸Aramis Site 124, Los Angeles, California, United States
🇺🇸Aramis Site 102, Newport Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath